

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+2.73%
+2.34%
+0.65%
+9.72%
+2.63%
MRK
Merck Company
$87.69
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued
Risk Analysis

Investors losing their confidence
Chart
$78.56 (+11.62%)
$80.17 (+9.38%)
$77.14 (+13.68%)
$100.73 (-12.95%)
MRK has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

MRK overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
MRK Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MRK Street view is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayNVS
130.80
-0.60%
AZN
82.96
-0.53%
PFE
24.72
+0.14%
SNY
51.43
+3.84%
LLY
829.71
+0.91%
What is MRK current stock price?
What are MRK stock strengths?
What risks are associated with MRK stock?
When is MRK next earnings report?
What is MRK market cap and volume?
What is MRK's current Stock IQ?
Should I buy MRK stock right now?
Is MRK a Strong Buy right now?
What does a 'Strong Buy' rating mean for MRK?
What does a 'Strong Sell' rating mean for MRK?
What factors influence MRK's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+2.73%
+2.34%
+0.65%
+9.72%
+2.63%
MRK
Merck Company
Current Price
$87.69
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued
Risk Analysis

Investors losing their confidence
Linked to MRK
NVS
130.80
-0.60%
AZN
82.96
-0.53%
PFE
24.72
+0.14%
SNY
51.43
+3.84%
LLY
829.71
+0.91%
Chart
$78.56 (+11.62%)
$80.17 (+9.38%)
$77.14 (+13.68%)
$100.73 (-12.95%)
MRK Analysts Opinion
MRK Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
MRK Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
MRK Street view is bullish and have positive views on the near-term outlook
MRK has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Average key support and resistance price levels.
MRK Latest Analysis
Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24 Companies and 26 Therapies | DelveInsight. Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24 Companies and 26 Therapies |. DelveInsightThe hidradenitis suppurativa market is poised for strong growth driven by increasing disease awareness earlier diagnosis and expanding treatment access. Advances in biologic and targeted therapies particularly the emergen
Thu Oct 23, 2025
Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Weeks Release. Merck (MRK) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thu Oct 23, 2025
Guru Fundamental Report for MRK - Peter Lynch. Below is Valideas guru fundamental report for MERCK &. CO INC (MRK). Of the 22 guru strategies we follow MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati
Thu Oct 23, 2025
FDA Grants Priority Review For Mercks KEYTRUDA And KEYTRUDA QLEX SBLAs In MIBC . (RTTNews) - Merck & Co Inc. (MRK) on Thursday said that the United States Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) for KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph
Thu Oct 23, 2025
MRK Quantitative Stock Analysis - Peter Lynch. Below is Valideas guru fundamental report for MERCK &. CO INC (MRK). Of the 22 guru strategies we follow MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati
Tue Oct 21, 2025
Peter Lynch Detailed Fundamental Analysis - MRK. Below is Valideas guru fundamental report for MERCK &. CO INC (MRK). Of the 22 guru strategies we follow MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati
Mon Oct 20, 2025
Will Declining Gardasil Sales Ail MRKs Top Line in Q3 Earnings?. Merck faces a sharp Gardasil slowdown as weak demand in China and Japan affects sales of the vaccine.
Fri Oct 17, 2025
Invo Fertility Stock Is Plunging After White House Announcement. ) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments .) to dramatically cut the cost of IVF medications. Under the agreement Merck'.s fertility drugs — like Gonal-f Ovidrel and Cetrotide — will be heavily discounted when used for IVF treatment saving patients approximately $2200 per treatment cycle.In return for the price reductions Merck will
Fri Oct 17, 2025
Peter Lynch Detailed Fundamental Analysis - MRK. Below is Valideas guru fundamental report for MERCK &. CO INC (MRK). Of the 22 guru strategies we follow MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relati
Fri Oct 17, 2025
Bank of America Securities Reduces PT on Merck & Co. Inc. (MRK) Keeps a Buy Rating.
Fri Oct 17, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.